Techstartups - Earlier today, we published a story about a new study published by NIH which shows that Hydroxychloroquine has been found to be more effective and potent than chloroquine in vitro treatment of coronavirus.
Now, a recent well controlled clinical study conducted by Didier Raoult? M.D/Ph.D, et. al in France showed that 100% of patients that received a combination of HCQ and Azithromycin tested negative and were virologically cured within 6 days of treatment.
In addition, recent guidelines from South Korea and China report that hydroxychloroquine and chloroquine are effective antiviral therapeutic treatments for novel coronavirus.
US Returnee Suspected of Having Coronavirus moved to 'Stroke Ward'
NYSC explains death of Corps member
Coronavirus: Churches, Mosques, schools shut in COVID-19 lockdown
Coronavirus pandemic could leave up to 24.7m unemployed says UN
A therapeutic agent that prevents infection with novel coronavirus is highly desirable–especially for persons with high-risk exposure (e.g healthcare professionals) as well as persons with comorbidities (heart disease, diabetes, etc) and compromised immune systems. Ground-breaking in vitro studies demonstrate potential efficacy of hydroxychloroquine as a prophylactic for novel coronavirus infection in primate cells.
The study is part of the initiative from an independent group of scientists and physicians working on an open-data clinical trial for prevention of COVID-19, through the use of hydroxychloroquine in combination with other therapeutic agents. The group is now calling on President Trump to allow Americans to use the drug.